去纤维钠适应症有什么？

What are the indications for defibrinated sodium? Defibrotide is a single-stranded oligonucleotide mixture with anti-thrombotic and fibrinolytic effects. Defibrotide is suitable for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), and renal or pulmonary dysfunction after hematopoietic stem cell transplantation (HSCT). Defibrotide is an adenosine receptor agonist with multiple effects. The adenosine A1/A2 receptors of endothelial cells are involved in the regulation of endothelial cells and the response of endothelial cells to injury. Defibrotide can act on these receptors to produce a variety of downstream effects. Defibrotide can also reduce the expression of cell adhesion molecules on the surface of endothelial cells, thereby reducing the adhesion of leukocytes to vascular endothelial cells and reducing the inflammatory damage of endothelial cells.

In addition, Defibrotide can also promote the release of prostaglandin I2 (PGI2) and prostaglandin E2 (PGE2), thereby causing blood vessel dilation, inhibiting platelet aggregation, and reducing ischemic damage. Studies have shown that Defibrotide can significantly increase the expression of thrombomodulin (TM) and tissue factor pathway inhibitors to produce anticoagulant effects.

The recommended dose of Defibrotide for adult and pediatric patients is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol. Defibrotide was administered for a minimum of 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue defibrotide until resolution of VOD or up to a maximum of 60 days. Defibrotide must be diluted before infusion. Prior to administration of Defibrotide, confirm that the patient is not experiencing clinically significant bleeding and is hemodynamically stable on no more than one vasopressor. Defibrotide was administered by constant intravenous infusion over a 2-hour period.

Clinical studies of defibrotide did not include sufficient numbers of subjects aged 65 and older to determine whether they responded differently than younger subjects. Other reported clinical experience has not identified differences in response between older and younger patients. Defibrotide may enhance the pharmacodynamic activity of antithrombotic/fibrinolytic agents such as heparin or alteplase. Concomitant use of Defibrotide with antithrombotic or fibrinolytic agents due to an increased risk of bleeding.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician. 

Recommended related articles: